The similarities of aromatase inhibitors outweigh the differences.
Standard
The similarities of aromatase inhibitors outweigh the differences. / Jänicke, Fritz.
In: ANTI-CANCER DRUG, Vol. 19, No. 2, 2, 2008, p. 7-9.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The similarities of aromatase inhibitors outweigh the differences.
AU - Jänicke, Fritz
PY - 2008
Y1 - 2008
N2 - Although the aromatase inhibitors (AIs) as a class exhibit clear differences in terms of their structure and mechanism of action, these differences do not always translate into clinically significant differences in patient outcomes. In fact, these differences may actually reflect differences in clinical trial design (i.e. upfront, sequential or switch therapy) or the patient population studied. The results of clinical trials demonstrate a clear superiority of third-generation AIs over tamoxifen. It will, however, be necessary to wait for the results of the ongoing head-to-head MA.27 and Novartis trials to determine whether there is any differentiation between the various third-generation AIs.
AB - Although the aromatase inhibitors (AIs) as a class exhibit clear differences in terms of their structure and mechanism of action, these differences do not always translate into clinically significant differences in patient outcomes. In fact, these differences may actually reflect differences in clinical trial design (i.e. upfront, sequential or switch therapy) or the patient population studied. The results of clinical trials demonstrate a clear superiority of third-generation AIs over tamoxifen. It will, however, be necessary to wait for the results of the ongoing head-to-head MA.27 and Novartis trials to determine whether there is any differentiation between the various third-generation AIs.
M3 - SCORING: Zeitschriftenaufsatz
VL - 19
SP - 7
EP - 9
JO - ANTI-CANCER DRUG
JF - ANTI-CANCER DRUG
SN - 0959-4973
IS - 2
M1 - 2
ER -
